ArticleACR open rheumatology2019

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years.

Janet E Pope et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.